Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples